Standout Papers

Guidelines for the diagnosis and treatment of chronic lymphocytic leuke... 2002 2026 2010 2018 2.2k
  1. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines (2008)
    Michael Hallek, Bruce D. Cheson et al. Blood
  2. The Clinical Sequelae of Intravascular Hemolysis and Extracellular Plasma Hemoglobin (2005)
    Russell P. Rother, Leonard Bell et al. JAMA
  3. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL (2018)
    Michael Hallek, Bruce D. Cheson et al. Blood
  4. The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria (2006)
    Peter Hillmen, Neal S. Young et al. New England Journal of Medicine
  5. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study (2002)
    Michael J. Keating, Ian W. Flinn et al. Blood
  6. Natural History of Paroxysmal Nocturnal Hemoglobinuria (1995)
    Peter Hillmen, S. M. Lewis et al. New England Journal of Medicine
  7. Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia (2018)
    John F. Seymour, Thomas J. Kipps et al. New England Journal of Medicine
  8. Guidelines for the diagnosis and management of adult aplastic anaemia (2015)
    Sally Killick, Nick Bown et al. British Journal of Haematology
  9. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2015)
    Barbara Eichhorst, Tadeusz Robak et al. Annals of Oncology
  10. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2020)
    Barbara Eichhorst, Tadeusz Robak et al. Annals of Oncology
  11. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study (2019)
    Jan A. Burger, Paul M. Barr et al. Leukemia
  12. Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (2019)
    Talha Munir, Jennifer R. Brown et al. American Journal of Hematology
  13. Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria (2021)
    Peter Hillmen, Jeff Szer et al. New England Journal of Medicine
  14. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia  (2022)
    Paul M. Barr, Carolyn Owen et al. Blood Advances

Immediate Impact

12 by Nobel laureates 7 from Science/Nature 71 standout
Sub-graph 1 of 19

Citing Papers

Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
2025 Standout
Diagnosis and Treatment of Chronic Lymphocytic Leukemia
2023 Standout
34 intermediate papers

Works of Peter Hillmen being referenced

Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib
2019
Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
2019 Standout
and 44 more

Author Peers

Author Last Decade Papers Cites
Peter Hillmen 13715 11714 9090 339 21.7k
Steven P. Treon 9984 5744 8533 464 18.8k
R. Kanti 15598 8866 11148 273 22.7k
Daniel Catovsky 19063 10150 13429 530 34.7k
Jan A. Burger 12612 7637 8272 427 20.5k
Tadeusz Robak 9615 5138 7531 688 18.7k
Tiziano Barbui 16252 2901 1862 545 29.6k
Emili Montserrat 10250 5161 9246 294 16.0k
Michele Baccarani 14203 3049 4366 704 28.3k
William G. Wierda 17768 8012 12673 821 30.9k
John F. Seymour 10380 3562 9515 548 23.0k

All Works

Loading papers...

Rankless by CCL
2026